You have accessJournal of UrologyCME1 Apr 2023MP29-15 REMOTELY-MONITORED SLEEP MEASURES IN PROSTATE CANCER PATIENTS UNDERGOING ANDROGEN DEPRIVATION THERAPY (ADT) Brandon Noorvash, Aubrey Jarman, Carolina Raines, Edwin M. Posadas, Howard M. Sandler, Stephen J. Freedland, and Gillian Gresham Brandon NoorvashBrandon Noorvash More articles by this author , Aubrey JarmanAubrey Jarman More articles by this author , Carolina RainesCarolina Raines More articles by this author , Edwin M. PosadasEdwin M. Posadas More articles by this author , Howard M. SandlerHoward M. Sandler More articles by this author , Stephen J. FreedlandStephen J. Freedland More articles by this author , and Gillian GreshamGillian Gresham More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003257.15AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Sleep disturbance is a common symptom experienced among men with prostate cancer (PC) undergoing ADT that can lead to increased fatigue, diminished quality of life, and poor clinical outcomes. Wearable activity monitors (e.g. Fitbits) allow for objective measures of sleep outside the clinical setting. Despite its importance, there is a current lack of information supporting the use of commercially available wearables for sleep monitoring among PC patients. Thus, we evaluated remotely-monitored longitudinal sleep measures in PC patients receiving ADT. METHODS: PC patients initiating ADT and recruited from Cedars-Sinai and the Durham VA wore a Fitbit Charge HR continuously for 8 weeks to capture daily activity and sleep and monthly electronic patient-reported sleep disturbance (NIH PROMIS survey) and insomnia (PRO-CTCAE). Objective and patient-reported sleep data were summarized, and changes were calculated at 4 and 8 weeks from baseline. RESULTS: A total of 25 patients were included in the analysis (median age 69, range 51-85, 64% Non-Hispanic White, 16% Black, 20% other race/ethnicity). Adherence to wearing the device was 100% at baseline, 88% at 4 weeks, and 76% at week 8. Sleep measures are summarized in /Table 1/. Objective sleep duration decreased over time (-1.5 hours at 8 weeks, p=0.02) and the number of sleep disturbances increased, although not statistically significant. Severity and interference of patient-reported insomnia (PRO-CTCAE) also worsened over time (Table 1). CONCLUSIONS: Our findings suggest that the use of wearables to remotely monitor sleep is feasible in PC patients. Sleep duration and quality were poor and worsened over time, with many awakenings and segmented sleep, which may be associated with treatment effects and other symptoms (e.g., hot flashes, nocturia). More research is needed to inform the development of tailored interventions to improve sleep in this population. Source of Funding: Department of Defense © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e387 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Brandon Noorvash More articles by this author Aubrey Jarman More articles by this author Carolina Raines More articles by this author Edwin M. Posadas More articles by this author Howard M. Sandler More articles by this author Stephen J. Freedland More articles by this author Gillian Gresham More articles by this author Expand All Advertisement PDF downloadLoading ...